Exchange Rates Wipe Out Growth For Abbott’s Established Unit
Executive Summary
Unfavorable foreign-exchange effects eradicated any organic growth for Abbott’s Established Pharmaceuticals unit in the second quarter and first half of 2019.
You may also be interested in...
Abbott’s Established Unit Grows By A Tenth
Abbott’s Established Pharmaceuticals business saw double-digit organic growth in the fourth quarter of 2019 on the back of its “unique branded generic strategy in emerging markets,” particularly in Latin America and Asia.
Abbott Sees Little Impact From Chinese Tenders
Competitive procurement practices for off-patent molecules in China are not affecting Abbott adversely because its local Established Pharmaceuticals portfolio is focused on niche, hard-to-make branded generics.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.